Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(16 sites)

United States

Site 02-012 - University of Chicago, Chicago, Illinois

Site 02-016 - Urology of Indiana, Greenwood, Indiana

Site 02-015 - Associated Medical Professionals of New York, Syracuse, New York

Site 02-017 - Central Ohio Urology Group, Gahanna, Ohio

Site 02-008 - MidLantic Urology, Bala-Cynwyd, Pennsylvania

Site 02-006 - Carolina Urologic Research Center, Myrtle Beach, South Carolina

Site 02-007 - Urology Associates, P. C, Nashville, Tennessee

Site 02-010 - Urology San Antonio P. A, San Antonio, Texas

Site 02-009 - Virginia Urology, Richmond, Virginia

Site 02-011 - University of Wisconsin Health University Hospital, Madison, Wisconsin

Canada

Site 01-005 - The Vancouver Prostate Centre - Diamond Health Care Centre - Vancouver General Hospital, Vancouver, British Columbia

Site 01-004 - Nova Scotia Health Authority - Centre for Applied Urology Research, Halifax, Nova Scotia

Site 01-014 - St. Joseph's Healthcare, Hamilton, Ontario

Site 01-002- London Health Sciences Centre - Victoria Hospital, London, Ontario

Site 01-001 - University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario

Site 01-003 - McGill University Health Centre - Glen-Cedars Cancer Centre, Montreal, Quebec